References
1. Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili S-M, Bahreini E. A comprehensive review of COVID-19 characteristics. Biological procedures online. 2020;22:1-10.
2. Kerget B, Kerget F, Koçak AO, et al. Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19? Lung. 2020;198(5):777-784.
3. Kerget B, Kerget F, Aksakal A, Aşkın S, Sağlam L, Akgün M. Evaluation of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels in COVID‐19 patients with macrophage activation syndrome and acute respiratory distress syndrome. Journal of Medical Virology. 2020.
4. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. Journal of Rehabilitation Medicine. 2020;52(5).
5. Park WB, Jun KI, Kim G, et al. Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome.Journal of Korean medical science. 2018;33(24).
6. Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. European Respiratory Journal. 2020;55(6).
7. Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology. In:2020.
8. Hui D, Joynt G, Wong K, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401-409.
9. Hui DS, Wong KT, Ko FW, et al. The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors. Chest.2005;128(4):2247-2261.
10. Ngai JC, Ko FW, Ng SS, TO KW, Tong M, Hui DS. The long‐term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15(3):543-550.
11. McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome.Autoimmunity reviews. 2020:102537.
12. Otsuka R, Seino K-i. Macrophage activation syndrome and COVID-19.Inflammation and regeneration. 2020;40(1):1-6.
13. Nusair S. Abnormal carbon monoxide diffusion capacity in COVID-19 patients at time of hospital discharge. European Respiratory Journal. 2020;56(1).
14. Lagadinou M, Solomou EE, Zareifopoulos N, Marangos M, Gogos C, Velissaris D. Prognosis of COVID-19: Changes in laboratory parameters.Age (yrs). 2020;62(13.4):47-16.42.
15. Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study.Respiratory medicine. 2006;100(12):2112-2120.
16. Lee CH, Goag EK, Lee SH, et al. Association of serum ferritin levels with smoking and lung function in the Korean adult population: analysis of the fourth and fifth Korean National Health and Nutrition Examination Survey. International journal of chronic obstructive pulmonary disease. 2016;11:3001.
17. Shibata Y, Abe S, Inoue S, et al. Relationship between plasma fibrinogen levels and pulmonary function in the Japanese population: the Takahata study. International journal of medical sciences.2013;10(11):1530.
18. Enomoto N, Oyama Y, Enomoto Y, et al. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis.The clinical respiratory journal. 2018;12(8):2378-2389.
19. Bargagli E, Madioni C, Bianchi N, Refini R, Cappelli R, Rottoli P. Serum analysis of coagulation factors in IPF and NSIP.Inflammation. 2014;37(1):10-16.